Login to Your Account

Sygnis Shares Plunge on AX200 Acute Ischemic Stroke Miss

By Cormac Sheridan
BioWorld Today Correspondent

Tuesday, December 20, 2011
Shares in Sygnis Pharma AG plunged more than 62 percent Friday on news that its lead drug AX200 failed to demonstrate efficacy in a 328-patient Phase IIb trial in acute ischemic stroke.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription